Skip to main content
SpringerLink
Log in

Classification of Conditioning Regimens

  • Chapter
  • First Online:
Basics of Hematopoietic Stem Cell Transplant

  • 437 Accesses

Abstract

Whenever a patient is considered for stem cell transplant (SCT), the first decision is to select the most suitable conditioning regimen for the patient. Various radio-chemotherapeutic regimens are available and which components need to be combined and how much aggressive or less intense regimen to be used remains a major concern because the challenge is to reduce the transplant-related mortality and simultaneously to avoid the rejection of the graft or to prevent the relapse of disease. Various factors have to be considered when deciding about the type of conditioning regimens including the disease status, patient’s age, co-morbidities, type of donor, etc.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55(6):1114–25.

    Article  CAS  PubMed  Google Scholar 

  3. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. 2014;23(21):2535–52.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kröger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hübel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J Clin Oncol. 2017;35(19):2157–64.

    Article  PubMed  Google Scholar 

  5. Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, et al. A comparison of the myeloablative conditioning regimen Fludarabine/Busulfan with cyclophosphamide/total body irradiation, for allogeneic stem cell transplantation in the modern era: a cohort analysis. Biol Blood Marrow Transplant. 2018;24(8):1733–40.

    Article  CAS  PubMed  Google Scholar 

  6. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.

    Article  CAS  PubMed  Google Scholar 

  7. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347–53.

    Article  CAS  PubMed  Google Scholar 

  8. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kassim AA, Chinratanalab W, Ferrara JLM, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: “what is the best recipe?”. Bone Marrow Transplant. 2005;36(7):565–74.

    Article  CAS  PubMed  Google Scholar 

  10. DeZern AE, Styler MJ, Drachman DB, Hummers LK, Jones RJ, Brodsky RA. Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases. Am J Blood Res. 2013;3(1):84–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, et al. Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant. 2016;22(11):1915–25.

    Article  CAS  PubMed  Google Scholar 

  12. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica. 2007;92(7):1004–6.

    Article  PubMed  Google Scholar 

  13. Gassmann W, Uharek L, Wottge HU, Schmitz N, Löffler H, Mueller-Ruchholtz W. Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation. Blood. 1988;72(5):1574–9.

    Article  CAS  PubMed  Google Scholar 

  14. Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: Alison MR, editor. The cancer handbook. Chichester: Wiley; 2005.

    Google Scholar 

  15. Blaise D, Castagna L. Do different conditioning regimens really make a difference? Hematology Am Soc Hematol Educ Program. 2012;2012:237–45.

    Article  PubMed  Google Scholar 

  16. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant. 1990;6(3):155–61.

    CAS  PubMed  Google Scholar 

  17. Kassim AA, Savani BN. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther. 2017;10(4):245–51.

    Article  CAS  PubMed  Google Scholar 

  18. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111(1):18–29.

    CAS  PubMed  Google Scholar 

  19. Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001;7(9):473–85.

    Article  CAS  PubMed  Google Scholar 

  20. Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant. 2007;39(5):255–68.

    Article  CAS  PubMed  Google Scholar 

  21. Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28–39.

    Article  PubMed  Google Scholar 

  22. Forman SJ, Negrin RS, Antin JH, Appelbaum FR. Thomas’ hematopoietic cell transplantation: stem cell transplantation. Hoboken, NJ: Wiley; 2015.

    Book  Google Scholar 

  23. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission–a review from the Acute Leukemia working party of the EBMT. Haematologica. 2015;100(7):859–69.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann N Y Acad Sci. 2001;938:328–39.

    Article  CAS  PubMed  Google Scholar 

  26. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–400.

    Article  CAS  PubMed  Google Scholar 

  27. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101(4):1620–9.

    Article  CAS  PubMed  Google Scholar 

  28. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, et al. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19(9):1340–7.

    Article  CAS  Google Scholar 

  29. Ballen KK, Colvin G, Porter D, Quesenberry PJ. Low dose total body irradiation followed by allogeneic lymphocyte infusion for refractory hematologic malignancy—an updated review. Leuk Lymphoma. 2004;45(5):905–10.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, et al. Engraftment of allogeneic Hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531–6.

    Article  CAS  PubMed  Google Scholar 

  31. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 1999;5(4):192–203.

    Article  CAS  Google Scholar 

  32. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–64.

    Article  CAS  PubMed  Google Scholar 

  33. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Mattsson J, Uzunel M, Remberger M, Ringdén O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation. 2001;71(3):433–9.

    Article  CAS  PubMed  Google Scholar 

  35. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, pharmacodynamics, and pharmacogenomics of immunosuppressants in allogeneic hematopoietic cell transplantation: part II. Clin Pharmacokinet. 2016;55(5):551–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Buschfort C, Muller MR, Seeber S, Rajewsky MF, Thomale J. DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level. Cancer Res. 1997;57(4):651–8.

    CAS  PubMed  Google Scholar 

  37. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. a mechanism for cytotoxicity. J Biol Chem. 1990;265(27):16617–25.

    Article  CAS  PubMed  Google Scholar 

  38. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001;7(11):3580–9.

    CAS  PubMed  Google Scholar 

  39. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006;54(12):3750–60.

    Article  PubMed  Google Scholar 

  40. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93–103.

    Article  CAS  PubMed  Google Scholar 

  41. Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, et al. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. Transl Res. 2016;175:103–115.e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008;14(6):672–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Resnick IB, Aker M, Tsirigotis P, Shapira MY, Abdul-Hai A, Bitan M, et al. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Bone Marrow Transplant. 2007;40(10):957–64.

    Article  CAS  PubMed  Google Scholar 

  44. Resnick IB, Aker M, Shapira MY, Tsirigotis PD, Bitan M, Abdul-Hai A, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133(6):649–54.

    Article  CAS  PubMed  Google Scholar 

  45. Bryant A, Nivison-Smith I, Pillai ES, Kennedy G, Kalff A, Ritchie D, et al. Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients. Bone Marrow Transplant. 2014;49(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  46. Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R. Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant. 2016;51(2):232–40.

    Article  CAS  PubMed  Google Scholar 

  47. Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, et al. A comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation, for allogeneic stem cell transplantation in the modern era: a cohort analysis. Biol Blood Marrow Transplant. 2018;24(8):1733–40.

    Article  CAS  PubMed  Google Scholar 

  48. Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525–36.

    Article  CAS  PubMed  Google Scholar 

  50. Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, et al. Myeloablative flu/Bu conditioning provides similar overall survival and lower non-relapse mortality compared to traditional Bu/cy or cy/TBI in Allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23(3):S273.

    Article  Google Scholar 

  51. Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, et al. Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22(8):1424–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Giralt S. Busulfan-based conditioning regimens: not all partners are equal. Lancet Oncol. 2015;16(15):1448–9.

    Article  PubMed  Google Scholar 

  53. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31(6):701–9.

    Article  CAS  PubMed  Google Scholar 

  54. Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129–46.

    Article  PubMed  Google Scholar 

  55. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–63.

    Article  CAS  PubMed  Google Scholar 

  56. Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40(6):541–7.

    Article  CAS  PubMed  Google Scholar 

  57. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104(3):857–64.

    Article  PubMed  Google Scholar 

  59. Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97(9):2574–9.

    Article  CAS  PubMed  Google Scholar 

  60. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108–14.

    Article  CAS  PubMed  Google Scholar 

  61. Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Kami M, et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol. 2003;121(2):296–303.

    Article  PubMed  Google Scholar 

  62. Mapara MY, Kim YM, Wang SP, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100(5):1903–9.

    Article  CAS  PubMed  Google Scholar 

  63. Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, et al. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Transplantation. 2008;86(7):968–76.

    Article  PubMed  Google Scholar 

  64. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104(3):865–72.

    Article  PubMed  Google Scholar 

  65. Sharma SK, Choudhary D, Doval D, Khandelwal V, Patel A, Setia R, et al. Myeloablative versus reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplant for acute myeloid leukemia and myelodysplastic syndrome: a retrospective analysis. Indian J Hematol Blood Transfus. 2020;37:472. https://doi.org/10.1007/s12288-020-01386-6.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. Blood Rev. 2005;19(3):153–64.

    Article  PubMed  Google Scholar 

  67. Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011;128(12):2911–22.

    Article  CAS  PubMed  Google Scholar 

  68. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–9.

    Article  CAS  PubMed  Google Scholar 

  69. Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, et al. Addition of 10-day Decitabine to Fludarabine/Total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T Cell responses. Biol Blood Marrow Transplant. 2016;22(6):1000–8.

    Article  CAS  PubMed  Google Scholar 

  70. Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, et al. Fludarabine-based conditioning secures engraftment of second Hematopoietic Stem Cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007;13(11):1313–23.

    Article  CAS  PubMed  Google Scholar 

  71. Korula A, Pn N, Devasia A, Lakshmi KM, Abraham A, Sindhuvi E, et al. Second hematopoietic stem cell transplant for thalassemia major: improved clinical outcomes with a Treosulfan-based conditioning regimen. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2018;24(1):103–8.

    Article  Google Scholar 

  72. Markey KA, MacDonald KPA, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014;124(3):354–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, et al. Fludarabine/Busulfan versus Fludarabine/Melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma. Biol Blood Marrow Transplant. 2016;22(10):1808–15.

    Article  CAS  PubMed  Google Scholar 

  74. Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin’s lymphoma in recent years: a retrospective analysis of the lymphoma working Party of the European Group for Blood and marrow transplantation. Ann Oncol. 2016;27(12):2251–7.

    Article  CAS  PubMed  Google Scholar 

  75. Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, et al. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study. Br J Haematol. 2015;168(6):824–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-oncology and Bone Marrow Transplantation, Venkateshwar Hospital, New Delhi, Delhi, India

    Sanjeev Kumar Sharma

Authors
  1. Sanjeev Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, S.K. (2023). Classification of Conditioning Regimens. In: Basics of Hematopoietic Stem Cell Transplant. Springer, Singapore. https://doi.org/10.1007/978-981-19-5802-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5802-1_16

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5801-4

  • Online ISBN: 978-981-19-5802-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation